Photocure ASA (PHCUF) has released an update.
Photocure ASA has launched a new initiative to expand access to blue light cystoscopy for bladder cancer treatment in the U.S. by introducing a mobile equipment model in partnership with ForTec Medical and Karl Storz. This model circumvents traditional capital budgeting hurdles in hospitals, allowing for per-case usage and operational budgeting, with plans for a wider rollout of additional mobile units later in the year. The initiative aims to enhance bladder cancer care by enabling more facilities to utilize the advanced diagnostic technology without the upfront investment.
For further insights into PHCUF stock, check out TipRanks’ Stock Analysis page.
